What Is Tesamorelin?
Tesamorelin is a synthetic GHRH analog consisting of 44 amino acids identical to endogenous human growth hormone-releasing hormone, modified with a trans-3-hexenoic acid group that enhances stability and bioavailability. Developed by Theratechnologies Inc., it is the only FDA-approved growth hormone-releasing hormone analog currently on the market. Other GHRH analogs include CJC-1295 and sermorelin, which are commonly used off-label for similar purposes.
The distinguishing mechanism separates tesamorelin from other growth hormone secretagogues. Rather than directly introducing synthetic hormone, tesamorelin stimulates pituitary hormone production naturally. This approach maintains the natural pulsatile release pattern of GH and preserves the hypothalamic-pituitary feedback loop, potentially reducing the risk of pituitary suppression associated with direct HGH administration.How It Works
Pituitary Stimulation and GH Release
The mechanism involves tesamorelin binding to growth hormone-releasing hormone receptors (GHRH-R) located on somatotroph cells in the anterior pituitary gland. This binding triggers signaling cascades stimulating synthesis and secretion of endogenous growth hormone. The process mimics natural physiological mechanisms by which hypothalamic GHRH regulates hormone production, resulting in pulsatile GH release rather than the continuous elevated levels seen with exogenous GH administration.
IGF-1 Elevation and Metabolic Effects
Released growth hormone subsequently stimulates hepatic production of insulin-like growth factor-1 (IGF-1). Clinical evidence demonstrates tesamorelin administration increases IGF-1 levels by approximately 50-100 ng/mL from baseline. This elevation in IGF-1 mediates composition effects including enhanced lipolysis and increased protein synthesis. The metabolic effects on glucose are complex: while IGF-1 can improve insulin sensitivity, GH itself can cause insulin resistance, and the FDA label includes glucose monitoring as a clinical consideration for tesamorelin use.
Visceral Fat Reduction Mechanism
The most documented effect involves visceral adipose tissue reduction. Growth hormone promotes lipolysis by activating hormone-sensitive lipase in adipocytes, facilitating triglyceride breakdown into free fatty acids and glycerol. Visceral fat cells demonstrate particular responsiveness to GH-mediated lipolysis due to higher beta-adrenergic receptor density and greater lipolytic hormone sensitivity. Studies documented reductions in visceral adipose tissue of 10-18% (measured by CT scan) over 26-52 weeks of treatment.
Neuroprotective and Cognitive Effects
Emerging research suggests potential cognitive benefits, particularly in aging populations. A randomized controlled trial in older adults demonstrated improvements in executive function and verbal memory following 20 weeks of tesamorelin administration. These effects presumably result from IGF-1's neuroprotective properties, including enhanced neuronal survival, synaptic plasticity, and reduced neuroinflammation.